Trial Profile

An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lixmabegagene relduparvovec (Primary)
Indications Gangliosidoses
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors LYSOGENE

Most Recent Events

09 Jun 2023 This trial has been Discontinued in France, according to European Clinical Trials Database record.
07 Jun 2023 Status changed from active, no longer recruiting to discontinued.
30 Aug 2022 Planned End Date changed from 1 Jun 2025 to 1 Jan 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com